Примери за използване на Patients with schizophrenia на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
This drug has been used to treat patients with schizophrenia.
Patients with schizophrenia may be completely absent an adequate response to the usual stuff.
Abilify is an antipsychotic medicine for patients with schizophrenia and bipolar I disorder.
Quite often, patients with schizophrenia are starting to see non-existent personality and spirit, while they they seem quite real.
A 2011 study evaluated the effects of l-theanine on anxiety symptoms of patients with schizophrenia.
The study examined 98 patients with schizophrenia and 83 without the condition.
Disruption of the delta-catenin gene has also been observed in some patients with schizophrenia.
One study involved 344 patients with schizophrenia and the second study involved 314 patients with bipolar disorder.
ADASUVE is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.
Patients with schizophrenia often observed inadequate reaction to the words of relatives of people who only wish to help them.
Cognitive disorders in patients are similar, butsomewhere less important, those of the patients with schizophrenia.
In 44 patients with schizophrenia 65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
Following administration of 12.5 mg/day cariprazine to patients with schizophrenia, 20.8% of the dose was excreted in urine as cariprazine and its metabolites.
In 44 patients with schizophrenia> 65 years of age, dosing from 5 to 20 mg/ day was not associated with any distinguishing profile of adverse events.
The injection is used only forquickly controlling agitation or disturbed behaviour in patients with schizophrenia or bipolar I disorder.
In 44 patients with schizophrenia>65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
The CHMP noted that the studies comparing Xeplion with placebo andrisperidone showed that the medicine is beneficial to patients with schizophrenia.
In 44 patients with schizophrenia older than 65 years, the use of olanzapine in doses of 5-20 mg/ day did not lead to differences in the profile of adverse events.
Malignant neuroleptic syndrome(CNS) is one of the most dangerous complications of neuroleptic therapy,often leading to the death of patients with schizophrenia.
In 44 patients with schizophrenia> 65 years of age, dosing from 5 to 20 mg/ day was not associated with any distinguishing profile of adverse events.
In addition, the injection has been shown to be effective atquickly controlling agitation or disturbing behaviour in patients with schizophrenia or bipolar I disorder.
Patients with schizophrenia and a large number of MPA more likely to have an unfavorable course of mental illness and manifestations of therapeutic resilience.
Worsening of psychotic symptoms can occur when antidepressants are administered to patients with schizophrenia or other psychotic disturbances; paranoid thoughts can be intensified.
For instance, patients with schizophrenia may have chemical imbalances in the brain and that those with Alzheimer's disease experience brain cell degeneration.
A majority of the patients in both Phase 3 studies were smokers with about 82% of the patients with schizophrenia and 74% of the patients with bipolar disorder currently smoking.
However, since patients with schizophrenia often present with acquired risk factors for venous thromboembolism all possible risk factors of VTE e.g.
Most people cannot tickle themselves, but some patients with schizophrenia can, suggesting that their brain interprets sensory perceptions from their own body differently.
In patients with schizophrenia, the most severe and chronic diseases of the psyche are problems when interacting with other people at work or in school, in relationships with relatives.
In placebo controlled clinical studies in adult patients with schizophrenia there was an increased occurrence of EPS following treatment with lurasidone compared to placebo.
Approximately one third of patients with schizophrenia(in some countries, up to half of the patients) have problems related to alcohol and substance abuse.